Business
Notice of Preliminary Results
Notice of Preliminary Results.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 1623G Evgen Pharma PLC 25 May 2017 \n\n \n\n\n\n\nFor immediate release\n\n\n 25 May 2017\n\n\n\n\n \n\n\n \n\n\n\n\n \n \n \n \n \n \nEvgen Pharma plc \n (\"Evgen Pharma\" or \"the Company\")\nNotice of Preliminary Results\nEvgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its preliminary results for the year ended 31 March 2017 on Tuesday 13 June 2017.\nA meeting for analysts will be held at 11.00am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. For further information, or to register attendance, please contact Buchanan at the contact details below.\n \nEnquiries:\n \n\n\n\n\nEvgen Pharma plc\nDr Stephen Franklin, CEO\nRichard Moulson, CFO\nwww.evgen.com\n\n\nc/o +44 (0) 20 7466 5000\n \n\n\n\n\n \n\n\n \n\n\n\n\nBuchanan\nMark Court, Sophie Cowles, Stephanie Watson\n\n\n+44 (0) 20 7466 5000\n \n\n\n\n\n \n\n\n \n\n\n\n\nNorthland Capital Partners Limited\nMatthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance)\nJohn Howes and Rob Rees (Corporate Broking)\n\n\n+44 (0) 20 3861 6625\n\n\n\n\n\n\n\n\n\nNotes for editors:\nAbout Evgen Pharma plc\nEvgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. \nEvgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. \nFor further information, please visit: www.evgen.com\nFor commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/\n\nThis information is provided by RNSThe company news...